Objective:To explore the differential diagnostic value of three gastric function indicators and Helicobacter pylori ( Hp) antibody combined detection in early gastric cancer and precancerous lesions. Methods:A total of 103 patients with gastric cancer (gastric cancer group), 103 patients with precancerous lesions (precancerous lesion group) and 103 healthy physical examination subjects (healthy group) admitted to the Emergency Management Department Emergency General Hospital from December 2020 to December 2022 were retrospectively selected as the study objects. Three gastric function tests and 14C breath test were performed in all three groups. The levels of three gastric function indicators and Hp antibody were compared among the three groups. According to the results of 14C breath test, gastric cancer patients were divided into the positive group and the negative group, and the levels of the three gastric function indicators were compared between the two groups. Results:The serum levels of pepsinogen Ⅱ (PGⅡ) and gastrin 17 (G-17) in the gastric cancer group were higher than those in the precancerous lesion group and healthy group: (18.32 ± 4.72) μg/L vs. (13.83 ± 3.63), (11.56 ± 3.47) μg/L; (74.82 ± 8.89) μg/L vs. (61.07 ± 7.51), (49.14 ± 5.29) μg/L; the levels of pepsinogen Ⅰ (PGⅠ) and pepsinogen ratio (PGR, PGⅠ/ PGⅡ) were lower than those in the precancerous lesion group and healthy group: (35.83 ± 5.93) μg/L vs. (73.05 ± 7.23), (86.27 ± 8.48) μg/L; 1.96 ± 0.54 vs. 5.28 ± 1.00, 7.46 ± 1.02, there were statistical differences ( P<0.05). The positive rates of Hp antibody in gastric cancer group, precancerous lesion group and healthy group were 65.05% (67/103), 33.01%(34/103) and 11.65% (12/103), respectively, there was a statistically significant difference in the positive rates of Hp antibody among the three groups ( χ2 = 64.15, P<0.05). The positive rate of Hp antibody was the highest in gastric cancer group, followed by precancer group, and the lowest in healthy group.The levels of PGⅠand PGR in patients with positive 14C breath test in the gastric cancer group were lower than those with negative results: (25.79 ± 3.63) μg/L vs. (41.82 ± 4.71) μg/L, 1.28 ± 0.42 vs. 2.40 ± 0.56, while the levels of PGⅡ and G-17 were higher than those with negative results: (20.35 ± 3.59) μg/L vs. (17.46 ± 3.52) μg/L, (83.72 ± 10.84) μg/L vs. (65.07 ± 7.76) μg/L, there were statistical differences ( P<0.05). Conclusions:The combined detection of gastric function and Hp antibody can serve as important screening indicator for evaluating gastric cancer and precancerous lesions.

Objective:To explore the differential diagnostic value of three gastric function indicators and Helicobacter pylori ( Hp) antibody combined detection in early gastric cancer and precancerous lesions. Methods:A total of 103 patients with gastric cancer (gastric cancer group), 103 patients with precancerous lesions (precancerous lesion group) and 103 healthy physical examination subjects (healthy group) admitted to the Emergency Management Department Emergency General Hospital from December 2020 to December 2022 were retrospectively selected as the study objects. Three gastric function tests and 14C breath test were performed in all three groups. The levels of three gastric function indicators and Hp antibody were compared among the three groups. According to the results of 14C breath test, gastric cancer patients were divided into the positive group and the negative group, and the levels of the three gastric function indicators were compared between the two groups. Results:The serum levels of pepsinogen Ⅱ (PGⅡ) and gastrin 17 (G-17) in the gastric cancer group were higher than those in the precancerous lesion group and healthy group: (18.32 ± 4.72) μg/L vs. (13.83 ± 3.63), (11.56 ± 3.47) μg/L; (74.82 ± 8.89) μg/L vs. (61.07 ± 7.51), (49.14 ± 5.29) μg/L; the levels of pepsinogen Ⅰ (PGⅠ) and pepsinogen ratio (PGR, PGⅠ/ PGⅡ) were lower than those in the precancerous lesion group and healthy group: (35.83 ± 5.93) μg/L vs. (73.05 ± 7.23), (86.27 ± 8.48) μg/L; 1.96 ± 0.54 vs. 5.28 ± 1.00, 7.46 ± 1.02, there were statistical differences ( P<0.05). The positive rates of Hp antibody in gastric cancer group, precancerous lesion group and healthy group were 65.05% (67/103), 33.01%(34/103) and 11.65% (12/103), respectively, there was a statistically significant difference in the positive rates of Hp antibody among the three groups ( χ2 = 64.15, P<0.05). The positive rate of Hp antibody was the highest in gastric cancer group, followed by precancer group, and the lowest in healthy group.The levels of PGⅠand PGR in patients with positive 14C breath test in the gastric cancer group were lower than those with negative results: (25.79 ± 3.63) μg/L vs. (41.82 ± 4.71) μg/L, 1.28 ± 0.42 vs. 2.40 ± 0.56, while the levels of PGⅡ and G-17 were higher than those with negative results: (20.35 ± 3.59) μg/L vs. (17.46 ± 3.52) μg/L, (83.72 ± 10.84) μg/L vs. (65.07 ± 7.76) μg/L, there were statistical differences ( P<0.05). Conclusions:The combined detection of gastric function and Hp antibody can serve as important screening indicator for evaluating gastric cancer and precancerous lesions.